NurExone Biologic Inc.
NRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.35% | -52.62% | -50.39% | -38.58% | -8.12% |
| Total Depreciation and Amortization | 248.98% | 189.80% | 169.05% | 157.58% | 58.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.77% | 94.66% | 80.31% | 50.23% | 102.35% |
| Change in Net Operating Assets | 100.87% | 192.81% | 98.96% | -23,175.00% | -227.00% |
| Cash from Operations | -33.97% | -22.60% | -23.05% | -66.20% | -22.25% |
| Capital Expenditure | 86.27% | -3.53% | -42.39% | -440.83% | -1,325.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.31% | -92.31% | -139.13% | -139.13% | -- |
| Cash from Investing | 86.15% | -7.04% | -56.99% | -578.35% | -1,297.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 38.71% | 44.12% | 10.71% | -7.14% | -55.00% |
| Issuance of Common Stock | 6.00% | -27.74% | -56.35% | 452.21% | 499.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -214.23% | -73.28% | -25.26% | -25.26% | 203.53% |
| Cash from Financing | -35.43% | -29.50% | -56.84% | 419.26% | 407.98% |
| Foreign Exchange rate Adjustments | -462.50% | -414.71% | -9,850.00% | -981.25% | 900.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -211.59% | -176.88% | -259.99% | 108.27% | 168.73% |